Phase I Trial of Cetuximab, Radiotherapy, and Ipilimumab in Locally Advanced Head and Neck Cancer.
Robert L FerrisJessica MoskovitzSheryl KunningAyana T RuffinCarly ReederJames OhrWilliam E GoodingSeungwon KimBrian J KarlovitsDario A A VignaliUmamaheswar DuvvuriJonas T JohnsonDaniel PetroDwight E HeronDavid A ClumpTullia C BrunoJulie E BaumanPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
The RP2D for ipilimumab plus standard cetuximab-radiotherapy is 1 mg/kg in weeks 5, 8, 11, and 14. The regimen is tolerable and yields acceptable survival without cytotoxic chemotherapy.